When she’s not working with patients, Dr. Galicki enjoys traveling, skiing, reading fiction, and attending live concerts.
Learn more about
How We Can Help You
Watch our FAQ videos with answers to many of the questions we receive on our treatments and services, including TMS therapy, Esketamine nasal spray, and ECT treatments. All FDA-approved treatments for advanced depression.
Check FAQs
Consultation with one of our Treatment Access Specialists
Schedule a visit with a clinician at one of our convenient locations. Contact us and our Patient Access Team will contact you within one business day to review your options and schedule an appointment.
Find a psychiatrist nearest to you
Our state-of-the-art mental health clinics are open during hours that accommodate your schedule and are conveniently located throughout Southern and Northern California, Texas, Georgia, and Washington.
Oana Galicki, MD
Dr. Galicki is a Board Certified psychiatrist who specializes in the treatment of mood and anxiety disorders and impact of social, psychological and behavioral factors on general health and quality of life.
Locations
We are here to help during COVID-19. We have video appointments available now.
To book an appointment call (844) 867-8444 or click here for help.
More about Oana Galicki, MD
Dr. Oana Galicki is an experienced and empathetic practitioner dedicated to helping her patients understand their mental health conditions and find appropriate treatments. She is humbled to walk the path to wellness with her patients, and help them transform their lives.
She has a strong academic and psychopharmacologic background as well as extensive training in various modalities of psychotherapy. With Mindful Health, Dr. Oana Galicki focuses in areas such as Medication management, TMS therapy, and Esketamine. She is determined to find what works best for each patient and work together to create a treatment plan for them.
Personal Interests
Education & Experience
Dr. Galicki earned a Medical Degree from Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. She completed her general psychiatry residency followed by a fellowship in Psychosomatic Medicine, at St. Luke’s-Roosevelt Medical Center, a training hospital of Columbia University College of Physicians and Surgeons in New York City.
Dr. Galicki continued on as a staff psychiatrist at St. Luke’s, where she ran the Consult Liaison service, as well as taught and supervised psychiatry residents and fellows. She has also conducted research and published papers on topics including treatment for depression in patients with Parkinson’s disease and Alzheimer’s disease prevention.
After moving to San Francisco in 2011, Dr. Galicki provided outpatient psychiatric care to diverse populations in community clinic and private practice settings. She decided to offer TMS therapy to patients upon seeing its remarkable effects on those who had not responded to other therapies. Dr. Galicki joined Mindful Health Solutions in 2016 and is certified in TMS.
Certifications & Memberships
- Board Certified, American Board of Psychiatry and Neurology
- Board Certified, American Board of Psychosomatic Medicine
- Member, American Psychiatric Association
- Member, Society of Liaison Psychiatry
- Member, Academy of Psychosomatic Medicine
Publications
Ho L., Spielman L., Petrescu (Galicki) O., Haroutunian V., Purohit D., Czernik A., Yemul S., Aisen P., Mohs R. and Pasinetti G. M.
Altered expression of A-type but not B-type synapsin isoform in the brain of cases at high risk for Alzheimer’s Disease assessed by DNA microarray. Neurosci Letter 298: 191-194 (2001).
Mirjany M., Ho L., Petrescu (Galicki) O., Ionescu A. and Pasinetti G. M.
Excitotoxicity but not â-amyloid toxicity recapitulates changes in gene expression in the brain of cases at high risk of Alzheimer’s Disease dementia. Poster. Soc. Neuroscience Meet. (2001).
Ferrando S. J., Barnhill J. W., Findler M. N., Godbold J., Veytsman M. D., Petrescu (Galicki) O., Marinelli L., Hesketh D., Scarano A., Mor N., Dalton A., Nasser S. and Di Rocco A.
Characterization of depression subtypes in Parkinson’s Disease. Poster. Parkinson’s Disease Conference (2004).
